Drug updated on 4/18/2024
| Dosage Form | Cream (topical; 1%) |
| Drug Class | Aryl hydrocarbon receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the topical treatment of plaque psoriasis in adults.
Summary
- Tapinarof (Vtama) is indicated for the topical treatment of plaque psoriasis in adults, showing superior efficacy to both placebo and calcipotriol across 2,408 patients in eight clinical studies.
- The information was derived from five systematic reviews/meta-analyses focusing on Tapinarof (Vtama) for the topical treatment of plaque psoriasis and atopic dermatitis.
- Despite a higher incidence of adverse events compared to placebo and calcipotriol, serious systemic adverse events were not reported with Tapinarof (Vtama) use, marking it as a safe treatment option.
- In comparison with benvitimod, another topical drug for psoriasis and atopic dermatitis involving 1,925 patients' studies, Tapinarof (Vtama) showed similar effectiveness but potentially safer or comparable safety profile under certain conditions due to absent data on serious adverse events.
- Among emerging treatments such as crisaborole and systemic therapies focusing on Janus kinase inhibitors targeting various interleukins for Atopic Dermatitis (AD), Tapinarof's (Vtama) unique mechanism provides an alternative route expanding the arsenal of available treatments.
- While not directly compared in trials against other drugs like crisaborole or ruxolitinib treating mild-to-moderate AD cases; insights suggest that all three present statistically significant improvements in disease severity with well-tolerated profiles positioning Tapinarof (Vtama) competitively within this landscape.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vtama (tapinarof) prescribing information. | 2022 | Dermavant Sciences Inc., Long Beach, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| 1% Tapinarof cream for the treatment of psoriasis: a network meta-analysis of randomized placebo- and calcipotriol- controlled trials. | 2023 | Archives of Dermatological Research |
| Benvitimod for the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials. | 2022 | Dermatologic Therapy |
| Application of benvitimod on psoriasis: a systematic review and meta-analysis of randomized controlled trials. a systematic review of benvitimod. | 2022 | Therapies |
| New treatments in atopic dermatitis. | 2021 | Annals of Allergy, Asthma & Immunology |
| Topical agents currently in phase II or phase III trials for atopic dermatitis. | 2020 | Journal of Drugs in Dermatology |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: a novel topical therapy targeting the aryl hydrocarbon receptor. | 2023 | Journal of Managed Care & Specialty Pharmacy |